home / stock / tcon / tcon news

TCON News and Press, TRACON Pharmaceuticals Inc. From 03/10/22

Stock Information
Company Name: TRACON Pharmaceuticals Inc.
Stock Symbol: TCON
Market: OTC
Website: traconpharma.com
Menu
TCON TCON Quote TCON Short TCON News TCON Articles TCON Message Board
Get TCON Alerts

News, Short Squeeze, Breakout and More Instantly...
TCON - TRACON Pharmaceuticals Announces FDA Approval of Amended ENVASARC Protocol

SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform...
TCON - Biotech 101 Lecture 3: Looking At Major Biotech Catalysts

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

TCON - TRACON to Report Fourth Quarter and Full Year 2021 Financial Results and Corporate Update on March 15, 2022

SAN DIEGO, March 04, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform...

TCON - TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer Institute

SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics today announced that the National Cancer Institute (NCI) has initiated a rand...
TCON - TRACON Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform ...

TCON - PYR, SPRB and BBIO among mid-day movers

Gainers: PyroGenesis Canada (NASDAQ:PYR) +72%. Microbot Medical MBOT +50%. CollPlant Biotechnologies CLGN +32%. Future FinTech FTFT +41%. American Virtual Cloud Technologies (NASDAQ:AVCT) +23%. Spruce Biosciences (NASDAQ:SPRB) +31%. Tarena International TEDU +19%. CNF...

TCON - Microbot Medical, CollPlant Biotechnologies leads healthcare gainers; BridgeBio Pharma, BiondVax Pharmaceuticals among major losers

Gainers: Microbot Medical (NASDAQ:MBOT) +51%, CollPlant Biotechnologies (NASDAQ:CLGN) +27%, Lucira Health (NASDAQ:LHDX) +14%, IceCure Medical (NASDAQ:ICCM) +13%, Cue Health (NASDAQ:HLTH) +12%. Losers: BridgeBio Pharma (NASDAQ:BBIO) -71%, Biond...
TCON - Tracon Pharma drops 9% despite 'positive' envafolimab results from ENVASARC trial

TRACON Pharmaceuticals (NASDAQ:TCON) announces that the Independent Data Monitoring Committee (IDMC) for the ongoing ENVASARC pivotal trial recommended continued accrual as planned in both cohort A of single agent envafolimab and cohort B of envafolimab given with Yervoy (ipilimumab). Shares ...

TCON - TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial

Pre-specified Interim Analysis Concluded with Recommendation to Continue the ENVASARC Trial Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) in Each Cohort Satisfied the Bar for Futility and Supports Continued Accrual Envafolimab Well Tolerated ...

TCON - Tracon Pharma stock jumps 13% on regulatory approval of envafolimab in China

TRACON Pharmaceuticals (NASDAQ:TCON) reports that its partners Alphamab Oncology and 3D Medicines (Beijing) Co., Ltd. have announced that envafolimab (KN035), the world's first single-domain PD-L1 antibody formulated for subcutaneous injection received marketing authorization from the Chinese...
Previous 10 Next 10